These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33089082)

  • 1. Evaluation of pain, quality of life, and patient satisfaction in parenterally treated patients with postmenopausal osteoporosis.
    Özsoy-Ünübol T; Akyüz G; Mirzayeva S; Güler T
    Turk J Phys Med Rehabil; 2020 Sep; 66(3):262-270. PubMed ID: 33089082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Denosumab and Zoledronic Acid in Postmenopausal Women With Osteoporosis: Bone Mineral Density (BMD) and Trabecular Bone Score (TBS).
    Kang T; Park SY; Lee SH; Park JH; Suh SW
    J Korean Med Sci; 2022 Apr; 37(13):e68. PubMed ID: 35380023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Oral Ibandronate versus Intravenous Zoledronic Acid on Bone Metabolism and Bone Mineral Density in Postmenopausal Japanese Women with Osteoporosis.
    Uehara M; Nakamura Y; Suzuki T; Nakano M; Takahashi J
    J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with acute-phase response of bisphosphonate-naïve or pretreated women with osteoporosis receiving an intravenous first dose of zoledronate or ibandronate.
    Popp AW; Senn R; Curkovic I; Senn C; Buffat H; Popp PF; Lippuner K
    Osteoporos Int; 2017 Jun; 28(6):1995-2002. PubMed ID: 28299378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for Osteoporosis.
    Lips P; Cooper C; Agnusdei D; Caulin F; Egger P; Johnell O; Kanis JA; Kellingray S; Leplege A; Liberman UA; McCloskey E; Minne H; Reeve J; Reginster JY; Scholz M; Todd C; de Vernejoul MC; Wiklund I
    Osteoporos Int; 1999; 10(2):150-60. PubMed ID: 10501796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.
    Miller PD; Pannacciulli N; Brown JP; Czerwinski E; Nedergaard BS; Bolognese MA; Malouf J; Bone HG; Reginster JY; Singer A; Wang C; Wagman RB; Cummings SR
    J Clin Endocrinol Metab; 2016 Aug; 101(8):3163-70. PubMed ID: 27270237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of recombinant human parathyroid hormone(1-84) in patients with postmenopausal osteoporosis: a prospective, open-label, single-arm, multicentre, observational cohort study of the effects of treatment on quality of life and pain--the PROPOSE study.
    Möricke R; Rettig K; Bethke TD
    Clin Drug Investig; 2011; 31(2):87-99. PubMed ID: 21155613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the Portuguese version of the quality of life questionnaire of the European foundation for osteoporosis (QUALEFFO-41) in Brazilian women with postmenopausal osteoporosis with vertebral fracture.
    de Oliveira Ferreira N; Arthuso M; da Silva RB; Pinto-Neto AM; Costa-Paiva L
    Clin Rheumatol; 2013 Nov; 32(11):1585-92. PubMed ID: 23609409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis-31 in Spanish postmenopausal women.
    González Matarín PJ; Martínez-Amat A; Lomas-Vega R; de Guevara NM; Díaz-Mohedo E; Martínez López E; García AB; Hita-Contreras F
    Menopause; 2014 May; 21(5):469-76. PubMed ID: 24080847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CLINICAL EVALUATION OF COST EFFICACY OF DRUGS FOR TREATMENT OF OSTEOPOROSIS: A META-ANALYSIS.
    Albert SG; Reddy S
    Endocr Pract; 2017 Jul; 23(7):841-856. PubMed ID: 28448754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
    Palacios S; Agodoa I; Bonnick S; Van den Bergh JP; Ferreira I; Ho PR; Brown JP
    J Clin Endocrinol Metab; 2015 Mar; 100(3):E487-92. PubMed ID: 25514106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis.
    Simpson EL; Martyn-St James M; Hamilton J; Wong R; Gittoes N; Selby P; Davis S
    Bone; 2020 Jan; 130():115081. PubMed ID: 31626995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life in women with postmenopausal osteoporosis: correlation between QUALEFFO 41 and SF-36.
    de Oliveira Ferreira N; Arthuso M; da Silva R; Pedro AO; Pinto Neto AM; Costa-Paiva L
    Maturitas; 2009 Jan; 62(1):85-90. PubMed ID: 19100693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life in Romanian postmenopausal women with osteoporosis and fragility fractures.
    Ciubean AD; Ungur RA; Irsay L; Ciortea VM; Borda IM; Onac I; Vesa SC; Buzoianu AD
    Clin Interv Aging; 2018; 13():2465-2472. PubMed ID: 30584286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The reliability and validity of the Turkish version of Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO).
    Koçyigit H; Gülseren S; Erol A; Hizli N; Memis A
    Clin Rheumatol; 2003 Feb; 22(1):18-23. PubMed ID: 12605312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Balloon kyphoplasty: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2004; 4(12):1-45. PubMed ID: 23074451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of quality of life in women with postmenopausal osteoporosis.
    Górczewska B; Jakubowska-Pietkiewicz E
    Psychiatr Pol; 2022 May; ():1-14. PubMed ID: 36370434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of patient-reported outcomes (PROs): treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea.
    Byun DW; Moon SH; Kim T; Lee HH; Park HM; Kang MI; Ha YC; Chung HY; Yoon BK; Kim TY; Chae SU; Shin CS; Yang KH; Lee JH; Chang JS; Kim SH; Kim IJ; Koh JM; Jung JH; Yi KW; Yoo JJ; Chung DJ; Lee YK; Yoon HK; Hong S; Kim DY; Baek KH; Kim HJ; Kim YJ; Kang S; Min YK
    J Bone Miner Metab; 2019 May; 37(3):563-572. PubMed ID: 30238428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid infusion for lumbar interbody fusion in osteoporosis.
    Tu CW; Huang KF; Hsu HT; Li HY; Yang SS; Chen YC
    J Surg Res; 2014 Nov; 192(1):112-6. PubMed ID: 24948545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
    Rosa J; Vanuga P; Payer J; Svobodník A
    Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.